 SpringWorks Therapeutics Inc NASDAQ: SWTX reports interim data from the first 20 adult patients in its ongoing Phase 2b ReNeu trial evaluating mirdametinib for NF1-associated plexiform neurofibromas NF1-PN. NF1, also called von Recklinghausens disease, is a genetic disorder characterized by the development of multiple noncancerous benign tumors of nerves and skin neurofibromas and areas of abnormal skin color pigmentation. 